p.52 抽出テキスト

Circulation. 2019;139:e1082–e1143. DOI: 10.1161/CIR.0000000000000625 June 18/25, 2019 e1133 CLINICAL STATEMENTS AND GUIDELINES

S4.4.4.2-5.	 Vodnala D, Rubenfire M, Brook RD. Secondary causes of dyslipidemia. Am J Cardiol. 2012;110:823–5. S4.4.4.2-6.	 Lloyd-Jones DM, Wilson PW, Larson MG, et al. Lifetime risk of coronary heart disease by cholesterol levels at selected ages. Arch Intern Med. 2003;163:1966–72. S4.4.4.2-7.	 Domanski M, Lloyd-Jones D, Fuster V, et al. Can we dramatically reduce the incidence of coronary heart disease? Nat Rev Cardiol. 2011;8:721–5. S4.4.4.2-8.	 Durrington PN, Soran H. Cholesterol levels should play a more important role in identifying statin recipients. Circulation. 2017;135:627–9. S4.4.4.2-9.	 Thanassoulis G, Pencina MJ, Sniderman AD. The benefit model for prevention of cardiovascular disease: an opportunity to harmonize guidelines. JAMA Cardiol. 2017;2:1175–6. S4.4.4.2-10.	 Berry JD, Dyer A, Cai X, et al. Lifetime risks of cardiovascular disease. N Engl J Med. 2012;366:321–9. S4.4.4.2-11.	 Lehr AL, Driver SL, Stone NJ. The ABCDs of lifestyle counseling. JAMA Cardiol. 2016;1:505–6. S4.4.4.2-12.	 Omura JD, Watson KB, Loustalot F, et al. Primary care providers’ awareness of physical activity-related intensive behavioral counseling services for cardiovascular disease prevention. Am J Health Promot. 2018. 890117118784226. S4.4.4.2-13.	 Domanski MJ, Fuster V, Diaz-Mitoma F, et al. Next steps in primary prevention of coronary heart disease: rationale for and design of the ECAD trial. J Am Coll Cardiol. 2015;66:1828–36. S4.4.4.2-14.	 Carr JJ, Jacobs DR Jr, Terry JG, et al. Association of coronary artery

calcium in adults aged 32 to 46 years with incident coronary heart disease and death. JAMA Cardiol. 2017;2:391–9.

4.4.4.3 Children and Adolescents

S4.4.4.3-1.	 Iannuzzi A, Licenziati MR, Vacca M, et al. Comparison of two diets of varying glycemic index on carotid subclinical atherosclerosis in obese children. Heart Vessels. 2009;24:419–24. S4.4.4.3-2.	 Murphy EC, Carson L, Neal W, et al. Effects of an exercise intervention using Dance Dance Revolution on endothelial function and other risk factors in overweight children. Int J Pediatr Obes. 2009;4:205–14. S4.4.4.3-3.	 Pratt RE, Kavey RE, Quinzi D. Combined dyslipidemia in obese children: response to a focused lifestyle approach. J Clin Lipidol. 2014;8:181–6. S4.4.4.3-4.	 de Ferranti SD, Milliren CE, Denhoff ER, et al. Providing food to treat adolescents at risk for cardiovascular disease. Obesity (Silver Spring). 2015;23:2109–17. S4.4.4.3-5.	 Niinikoski H, Lagstrom H, Jokinen E, et al. Impact of repeated dietary counseling between infancy and 14 years of age on dietary intakes and serum lipids and lipoproteins: the STRIP study. Circulation. 2007;116:1032–40. S4.4.4.3-6.	 Obarzanek E, Kimm SY, Barton BA, et al. Long-term safety and efficacy of a cholesterol-lowering diet in children with elevated low-density lipoprotein cholesterol: seven-year results of the Dietary Intervention Study in Children (DISC) Pediatrics. 2001;107:256–64. S4.4.4.3-7.	 Dorgan JF, Liu L, Barton BA, et al. Adolescent diet and metabolic syndrome in young women: results of the Dietary Intervention Study in Children (DISC) follow-up study. J Clin Endocrinol Metab. 2011;96:E1999–2008. S4.4.4.3-8.	 Wong H, Chahal N, Manlhiot C, et al. Flaxseed in pediatric hyperlipidemia: a placebo-controlled, blinded, randomized clinical trial of dietary flaxseed supplementation for children and adolescents with hypercholesterolemia. JAMA Pediatr. 2013;167:708–13. S4.4.4.3-9.	 Zachariah JP, Chan J, Mendelson MM, et al. Adolescent dyslipidemia and standardized lifestyle modification: benchmarking realworld practice. J Am Coll Cardiol. 2016;68:2122–3. S4.4.4.3-10.	 Torvik K, Narverud I, Ottestad I, et al. Dietary counseling is associated with an improved lipid profile in children with familial hypercholesterolemia. Atherosclerosis. 2016;252:21–7. S4.4.4.3-11.	 Koletzko B, Kupke I, Wendel U. Treatment of hypercholesterolemia in children and adolescents. Acta Paediatr. 1992;81:682–5. S4.4.4.3-12.	 Tershakovec AM, Shannon BM, Achterberg CL, et al. One-year follow-up of nutrition education for hypercholesterolemic children. Am J Public Health. 1998;88:258–61. S4.4.4.3-13.	 Kusters DM, Caceres M, Coll M, et al. Efficacy and safety of

ezetimibe monotherapy in children with heterozygous familial or nonfamilial hypercholesterolemia. J Pediatr. 2015;166:1377–84 e1-3. S4.4.4.3-14.	 Yeste D, Chacon P, Clemente M, et al. Ezetimibe as monotherapy

in the treatment of hypercholesterolemia in children and adolescents. J Pediatr Endocrinol Metab. 2009;22:487–92. S4.4.4.3-15.	 Clauss S, Wai KM, Kavey RE, et al. Ezetimibe treatment of pediatric patients with hypercholesterolemia. J Pediatr. 2009;154:869–72. S4.4.4.3-16.	 Sonnett T, Robinson J, Milani P, et al. Role of colesevelam in managing heterozygous familial hypercholesterolemia in adolescents and children. Adolesc Health Med Ther. 2010;1:53–60. S4.4.4.3-17.	 Wald DS, Kasturiratne A, Godoy A, et al. Child-parent screening for familial hypercholesterolemia. J Pediatr. 2011;159:865–7. S4.4.4.3-18.	 Wald DS, Bestwick JP, Morris JK, et al. Child-parent familial hypercholesterolemia screening in primary care. N Engl J Med. 2016;375:1628–37. S4.4.4.3-19.	 Ritchie SK, Murphy EC, Ice C, et al. Universal versus targeted blood cholesterol screening among youth: the CARDIAC project. Pediatrics. 2010;126:260–5. S4.4.4.3-20.	 Skovby F, Micic S, Jepsen B, et al. Screening for familial hypercholesterolaemia by measurement of apolipoproteins in capillary blood. Arch Dis Child. 1991;66:844–7. S4.4.4.3-21.	 Garcia RE, Moodie DS. Routine cholesterol surveillance in childhood. Pediatrics. 1989;84:751–5. S4.4.4.3-22.	 Ned RM, Sijbrands EJ. Cascade screening for familial hypercholesterolemia (FH) PLoS Curr. 2011;3:RRN1238. S4.4.4.3-23.	 Bender R, Bell DA, Hooper AJ, et al. Screening for familial hypercholesterolaemia. Pathology. 2012;44:122–8. S4.4.4.3-24.	 National Institute for Health and Care Excellence (NICE) (UK). Familial hypercholesterolaemia: identification and management. Available at: http://www.nice.org.uk/guidance/CG71. Accessed August 24, 2018. S4.4.4.3-25.	 Kit BK, Kuklina E, Carroll MD, et al. Prevalence of and trends in dyslipidemia and blood pressure among US children and adolescents, 1999–2012 JAMA Pediatr. 2015;169:272–9. S4.4.4.3-26.	 May AL, Kuklina EV, Yoon PW. Prevalence of cardiovascular disease risk factors among US adolescents, 1999–2008 Pediatrics. 2012;129:1035–41. S4.4.4.3-27.	 Lozano P, Henrikson NB, Morrison CC, et al. Lipid screening in childhood and adolescence for detection of multifactorial dyslipidemia: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2016;316:634–44. S4.4.4.3-28.	 Gidding SS, Champagne MA, de Ferranti SD, et al. The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association. Circulation. 2015;132:2167–92. S4.4.4.3-29.	 Lozano P, Henrikson NB, Dunn J, et al. Lipid screening in childhood and adolescence for detection of familial hypercholesterolemia: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2016;316:645–55. S4.4.4.3-30.	 Vuorio A, Kuoppala J, Kovanen PT, et al. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev. 2017;7:CD006401. S4.4.4.3-31.	 Schanberg LE, Sandborg C, Barnhart HX, et al. Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheum. 2012;64:285–96. S4.4.4.3-32.	 Ardoin SP, Schanberg LE, Sandborg CI, et al. Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein. Ann Rheum Dis. 2014;73:557–66. S4.4.4.3-33.	 Perak AM, Ning H, de Ferranti SD, et al. Long-term risk of atherosclerotic cardiovascular disease in US adults with the familial hypercholesterolemia phenotype. Circulation. 2016;134:9–19. S4.4.4.3-34.	 Neil HA, Hawkins MM, Durrington PN, et al. Non-coronary heart disease mortality and risk of fatal cancer in patients with treated heterozygous familial hypercholesterolaemia: a prospective registry study. Atherosclerosis. 2005;179:293–7. S4.4.4.3-35.	 Sniderman AD, Tsimikas S, Fazio S. The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies. J Am Coll Cardiol. 2014;63:1935–47. S4.4.4.3-36.	 Smith AJ, Turner EL, Kinra S. Universal cholesterol screening in childhood: a systematic review. Acad Pediatr. 2016;16:716–25. S4.4.4.3-37.	 Kerr M, Pears R, Miedzybrodzka Z, et al. Cost effectiveness of

cascade testing for familial hypercholesterolaemia, based on data from familial hypercholesterolaemia services in the UK. Eur Heart J. 2017;38:1832–9.

Downloaded from http://ahajournals.org by on October 7, 2026